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ISIBACKGROUND Patients with familial hypercholesterolemia (FH) are characterized by elevated atherogenic lipoprotein
particles, predominantly low-density lipoprotein cholesterol (LDL-C), which is associated with accelerated atherogenesis
and increased cardiovascular risk.
OBJECTIVES This study used 18F-ﬂuorodeoxyglucose positron emission tomography (18FDG-PET) to investigate
whether arterial inﬂammation is higher in patients with FH and, moreover, whether lipoprotein apheresis attenuates
arterial wall inﬂammation in FH patients.
METHODS In total, 38 subjects were recruited: 24 FH patients and 14 normolipidemic controls. All subjects underwent
FDG-PET imaging at baseline. Twelve FH patients who met the criteria for lipoprotein apheresis underwent apheresis
procedures followed by a second FDG-PET imaging 3 days (range 1 to 4 days) after apheresis. Subsequently, the target-
to-background ratio (TBR) of FDG uptake within the arterial wall was assessed.
RESULTS In FH patients, the mean arterial TBR was higher compared with healthy controls (2.12  0.27 vs. 1.92  0.19;
p¼0.03). A signiﬁcant correlationwasobservedbetweenbaseline arterial TBR and LDL-C (R¼0.37; p¼0.03) that remained
signiﬁcant after adjusting for statin use (b¼ 0.001; p¼ 0.02) and atherosclerosis risk factors (b¼ 0.001; p¼ 0.03). LDL-C
levels were signiﬁcantly reduced after lipoprotein apheresis (284  118 mg/dl vs. 127  50 mg/dl; p < 0.001). There was a
signiﬁcant reduction of arterial inﬂammation after lipoprotein apheresis (TBR: 2.05 0.31 vs. 1.91  0.33; p < 0.02).
CONCLUSIONS The arterial wall of FH patients is characterized by increased inﬂammation, which is markedly
reduced after lipoprotein apheresis. This lends support to a causal role of apoprotein B–containing lipoproteins in
arterial wall inﬂammation and supports the concept that lipoprotein-lowering therapies may impart anti-inﬂammatory
effects by reducing atherogenic lipoproteins. (J Am Coll Cardiol 2014;64:1418–26) © 2014 by the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
18FDG = 18F-
ﬂuorodeoxyglucose
BMI = body mass index
CRP = C-reactive protein
CT = computed tomography
CVD = cardiovascular disease
FH = familial
hypercholesterolemia
HDL-C = high-density
lipoprotein cholesterol
IQR = interquartile range
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1419A therosclerosis is a chronic, lipid-driven in-ﬂammatory disorder of the arterial wall(1). Lipid accumulation in the subintimal
compartment ignites a local inﬂammatory response,
perpetuated by oxidized lipoproteins and activated
macrophages (2). Findings of prior studies of
patients with cardiovascular disease (CVD) exemplify
the relevance of this process by demonstrating that
both a large lipid-rich necrotic core (3) and increased
arterial inﬂammation (4) strongly predict plaque
vulnerability and subsequent rupture. The detri-
mental interaction between lipids and inﬂammation
is a hallmark in patients suffering from familialSEE PAGE 1427
LDL-C = low-density
lipoprotein cholesterol
Lp(a) = lipoprotein(a)
MDS = most diseased segment
PET = positron
emission tomography
SUV = standardized
uptake value
TBR = target-to-background
ratio
TG = triglycerideshypercholesterolemia (FH). These patients are pre-
dominantly characterized by extremely elevated
low-density lipoprotein cholesterol (LDL-C) levels,
increased levels of inﬂammatory markers (e.g., C-
reactive protein [CRP]), and premature CVD (5,6).
Prior studies have demonstrated some beneﬁcial
effects of statin therapy in FH patients (7); however,
a substantial residual cardiovascular (CV) risk re-
mains (8), possibly as a result of the fact that many
FH patients do not reach target LDL-C levels by
statins.
The direct link between lipid accumulation and
induction of local inﬂammation has been widely
demonstrated. Potent lipid-lowering interventions
have been shown to attenuate the degree of arterial
wall and atherosclerotic plaque inﬂammation in
experimental animal models (9). In humans, high-
dose statin therapy has been proven to reduce
serum levels of inﬂammatory biomarkers (5,10) in-
dependent of the statin’s LDL-lowering effect (11).
During the last decade, assessment of the local in-
ﬂammatory activity of the arterial wall or athero-
sclerotic plaque has been introduced using novel
imaging strategies, including 18F-ﬂuorodeoxyglucose
positron emission tomography (18FDG-PET) (12). The
FDG signal has been shown to correlate with arterial
macrophage content (13) and is predictive of subse-
quent risk of atherothrombotic events (14). Recently,
rapid reduction of local arterial wall inﬂammation via
statin therapy intensiﬁcation was observed using
PET imaging and, once again, was independent
of lipid proﬁle changes (15). Taking the widelyto the contents of this paper to disclose. Drs. van Wijk and Sjouke contribut
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into account, we therefore cannot dissect
whether this statin-induced reduction in
arterial wall inﬂammation is merely LDL-C
dependent or due to pleiotropic, anti-
inﬂammatory effects.
In the present study, we assessed whether
patients with FH are characterized by
increased arterial wall inﬂammation as deter-
mined by 18FDG-PET/computed tomography
(CT) imaging. Subsequently, we explored
whether a potent nonpharmacological lipid-
lowering strategy can attenuate local arterial
wall inﬂammation.
METHODS
STUDY POPULATION. This pilot study com-
prised a cross-sectional analysis investi-
gating arterial 18F-FDG uptake in FH patients
versus healthy controls, as well as a pro-
spective interventional analysis examining
the effects of lipoprotein apheresis on arte-
rial 18F-FDG uptake. This study was con-
ducted at 2 centers: the Academic Medical
Center, Amsterdam, the Netherlands, and Massa-
chusetts General Hospital, Boston, Massachusetts.
For the cross-sectional analysis at the Academic
Medical Center, 18 patients with established FH
diagnosis were recruited from the outpatient clinic.
Healthy and normolipidemic controls without known
CVD were recruited via local advertisements. For the
prospective analysis, 12 FH patients (6 of whom
were also included in the cross-sectional analysis
of the study) meeting the eligibility criteria for lipo-
protein apheresis according to apheresis guidelines
(16) were included (6 from each center). Six FH
patients (50%) were apheresis naive, and 6 patients
had previously undergone lipoprotein apheresis.
Written informed consent was obtained from all par-
ticipants, and the local institutional review boards
approved the protocol.
18F-FDG PET/CT IMAGING. 18FDG-PET/CT imaging
was performed in all FH patients and healthy controls
at baseline. In the apheresis-naive FH patients (n ¼ 6)
treated with weekly lipoprotein-apheresis sessions,
a second 18FDG-PET/CT scan was performed after 8
weeks, 3 days after the last apheresis session (medianed equally to this work. Drs. Tawakol and Stroes are
ntin Fuster.
r. Valentin Fuster.
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days]). For FH patients on chronic apheresis therapy
(n ¼ 6), a 2-week washout period was introduced,
after which the baseline 18FDG-PET/CT scan was
performed. The second 18FDG-PET/CT scan in these
patients was performed after a single apheresis
episode (median interval: 3 days [IQR: 1 to 5 days]).
PET/CT imaging of the aorta and carotid arteries was
performed using a PET/CT scanner (Philips Gemini,
Philips, Best, the Netherlands, or similar). In brief,
patients were placed in a supine position for intra-
venous administration of 18FDG. Approximately 90
min after 18FDG injection (w180 MBq), a PET/CT scan
was performed in 2 separate positions. The ﬁrst po-
sition covered the carotid arteries extending inferi-
orly from the internal auditory meatus (15.5 cm) and
acquired in 3-dimensional mode for 15 min. The sec-
ond position covered the ascending aorta, aortic arch,
and upper thoracic part of the descending aorta.
Attenuation-corrected PET images were used for
analysis.
IMAGE ANALYSIS. All scans were analyzed by 1
investigator (M.H.M.), who was blinded to patient
characteristics and the temporal sequence of images.
Arterial 18FDG uptake was quantiﬁed by drawing a
region of interest around each artery on every slice of
the coregistered transaxial CT image. Subsequently,
the maximal arterial standardized uptake value
(SUVmax) was recorded as the maximal pixel activity
within the region of interest of every vessel slice.
The SUV is the decay-corrected tissue concentration
of 18FDG in kBq/ml, adjusted for the injected 18FDG
dose and patient’s body weight. The mean SUVmax
for each artery was derived as the average of the
SUVmax of the individual slices of that artery. The
mean arterial target-to-background ratio (TBR) was
calculated by correcting the mean SUVmax for average
background blood activity as detailed in prior studies
(15,17). Additionally, the artery with the highest FDG
uptake (mean TBR) at baseline was identiﬁed as the
index vessel, as previously described (18). There-
after, the average of the maximum TBR activity
within the most diseased segment (MDS) of the index
vessel (MDS TBR) was recorded. The MDS, deﬁned as
the 1.5-cm arterial segment that demonstrated the
highest FDG uptake at baseline, was calculated as a
mean of maximum TBR values derived from 3
contiguous axial segments as detailed in prior
studies (15).
L I POPROTE IN APHERES I S . Twelve FH patients
underwent lipoprotein-apheresis procedures per-
formed either with the Direct Adsorption of Lipo-
protein (DALI) system (Fresenius Medical Care, BadHomburg, Germany) or the Liposorber system
(Kaneka Corporation, Osaka, Japan). The apheresis
procedure–treated time/blood volume was individu-
ally calculated according to standard operating pro-
cedures. Blood samples were obtained on the day
of (n ¼ 10) or within 4 days (n ¼ 2) of PET/CT
imaging. Blood was centrifuged for 10 min at 3,000
rotations/min at 20C. Total cholesterol, high-density
lipoprotein cholesterol (HDL-C), and triglycerides
(TG) were measured by a commercially available
enzymatic colorimetric assay (Roche, Basel, Switzer-
land). LDL-C levels were calculated by the Friede-
wald formula (19). Lipoprotein(a) [Lp(a)] levels were
measured by a commercially available immuno-
turbidometric assay (Abbott Laboratories, Abbott
Park, Illinois), as was CRP (assay by Roche, Basel,
Switzerland).
STATISTICAL ANALYSIS. Continuous variables were
tested for normality of distribution using the Shapiro-
Wilk test and are expressed as mean  SD or median
(IQR) for normally and non-normally distributed
variables, respectively. Independent samples t tests
and Mann-Whitney U tests were used where appro-
priate to assess baseline differences between FH
patients and healthy controls. Categorical variables
are expressed as absolute numbers and percentages
throughout this paper, and the chi-square test is
employed for between-group analyses. To evaluate
the relationship between continuous variables [e.g.,
LDL-C, Lp(a), and arterial TBR] at baseline, Pearson’s
correlation coefﬁcient or Spearman’s r is reported
according to the distribution of variables. Further-
more, a linear regression model was ﬁtted when
adjustment for potential confounding variables was
required, and the unstandardized regression coefﬁ-
cient (b) is reported. For longitudinal analysis in the
12 patients undergoing lipoprotein apheresis, the
Wilcoxon signed rank test and paired-samples t test
were used where appropriate. To assess the rela-
tionship between lipoproteins and TBR in these pa-
tients, Spearman’s r was assessed in addition to a
linear mixed-model analysis to provide an estimate of
ﬁxed effect of different lipoproteins on TBR. In order
to limit the confounding effect of different imaging
instruments, all between-group comparisons of im-
aging endpoints (between FH and controls) were
conﬁned to subjects imaged on a single PET/CT
camera. By contrast, for longitudinal analyses (before
and after apheresis of FH patients), where the impact
of the imaging instrument is largely controlled for,
analysis included subjects from both institutions. A
2-sided p value <0.05 was considered statistically
signiﬁcant. All data were analyzed using IBM SPSS
software (version 21, Armonk, New York).
TABLE 1 Baseline Demographic and Clinical Characteristics of Subjects
Familial
Hypercholesterolemia
(n ¼ 24)
Healthy
Controls
(n ¼ 14) p Value
Age, yrs 56.79  5.64 63.21  7.4 0.005
Male 16 (66.7) 11 (78.6) 0.16
BMI, kg/m2 28.57  4.1 24.35  1.3 0.001
Current smoker 2 (8.3) 2 (14.3) 0.56
CVD 7 (29) 0 0.027
Blood pressure
Systolic, mm Hg 132.67  9.58 141.21  10.78 0.016
Diastolic, mm Hg 79.21  8.94 83.57  5.64 0.11
Total cholesterol, mg/dl 320.9  112.36 228.7  32.93 0.005
LDL cholesterol, mg/dl 236.4  108.3 147.02  31.14 0.005
HDL cholesterol, mg/dl 54.83  15.11 62.26  11.6 0.12
Triglycerides, mg/dl 140.27  75.5 109.4  79.7 0.24
Lipoprotein(a), nmol/l* 73 [43–401] 197 [40–480] 0.464
CRP, mg/l* 1.1 [0.6–2.0] 0.7 [0.4–1.0] 0.115
Statin use 11 (45.83) 0 N/A
Non-statin lipid-lowering
therapy†
11 (45.83) 0 N/A
Values are mean  SD, n (%) or median [interquartile range (IQR)]. *Data were available for
apheresis-naive patients only (n ¼ 6). †Eight subjects were receiving both a statin and a non-
statin lipid-lowering agent.
BMI ¼ body mass index; CRP ¼ C-reactive protein; CVD ¼ cardiovascular disease; HDL ¼ high-
density lipoprotein; LDL ¼ low-density lipoprotein; N/A ¼ not applicable.
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FIGURE 1 Higher Arterial TBR in FH Patients Than
Control Subjects
(A) Representative images of CT, PET, and fused PET/CT of the
aorta in a patient with FH (left) and an age-matched healthy
control (right). (B) Mean arterial TBR (average TBR of aorta and
carotids) is signiﬁcantly higher in patients with FH compared with
healthy controls. This difference remained signiﬁcant after
adjusting for statin use (b ¼ 0.25; p ¼ 0.01) and risk factors
of atherosclerosis (age, male, blood pressure, smoking)
(b ¼ 0.19; p ¼ 0.03). Error bars represent the standard error
of the mean. CT ¼ computed tomography; 18FDG ¼ 18F-ﬂuoro-
deoxyglucose; FH ¼ familial hypercholesterolemia; PET ¼ posi-
tron emission tomography; TBR ¼ target-to-background ratio.
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ARTERIAL WALL INFLAMMATION AND BLOOD
BIOMARKERS AT BASELINE. Baseline demographics
of 24 FH patients and 14 control subjects are outlined
in Table 1. Apart from clear differences in the lipid
proﬁle, the control subjects were older and had a
lower body mass index (BMI) compared with FH pa-
tients. Approximately 46% of FH patients were using
statins; most commonly, those who did not were
statin intolerant. Although the baseline LDL-C con-
centration in FH patients was signiﬁcantly highercompared with the control group, some patients
had modestly elevated LDL-C levels. The latter
ﬁnding might be due to intensive lipid-lowering ther-
apies in these patients. Baseline arterial TBR was
signiﬁcantly higher in FH patients compared with
control subjects (2.12  0.27 vs. 1.92  0.19; p ¼ 0.03)
(Figures 1A and 1B). This difference remained signiﬁ-
cant after excluding FH patients with prior CVD
(p ¼ 0.04).
Moreover, arterial TBR remained higher in FH pa-
tients after adjusting for statin use (b ¼ 0.25; p ¼ 0.01)
and risk factors of atherosclerosis (age, male, blood
pressure, and smoking) (b ¼ 0.19; p ¼ 0.03). A sig-
niﬁcant correlation was observed between baseline
arterial TBR and LDL-C (R ¼ 0.37; p ¼ 0.03) as well as
CRP level (R ¼ 0.48; p ¼ 0.006). The relationship
between baseline arterial TBR and LDL-C remained
signiﬁcant after adjustment for statin use (b ¼ 0.001;
p ¼ 0.02), and previously stated atherosclerosis risk
factors (b ¼ 0.001; p ¼ 0.03). Moreover, the relation-
ship between LDL-C and arterial inﬂammation
remained signiﬁcant (b ¼ 0.001; p ¼ 0.043) after
adjusting for the baseline factors that were signiﬁ-
cantly different between patient groups (FH diag-
nosis, age, BMI).
IMPACT OF LIPOPROTEIN APHERESIS ON ARTERIAL
INFLAMMATION. The characteristics of the 12 FH
patients treated with lipoprotein apheresis are
TABLE 2 Baseline and Post-Apheresis Characteristics of Patients Treated With
Lipoprotein Apheresis
Patients Treated With Lipoprotein Apheresis (n ¼ 12)
Age, yrs 57  5.8
Male 7 (58.3)
BMI, kg/m2 29.5  2.3
Current smoker 1 (8.3)
CVD 7 (58.3)
Blood pressure
Systolic, mm Hg 130.3  9.4
Diastolic, mm Hg 79.1  10.6
Statin use 3 (25)
Non-statin lipid-lowering therapy 2 (16.7%)
Pre-Apheresis Post-Apheresis Change (%) p Value
Mean arterial TBR 2.05  0.31 1.91  0.33 6.5 0.02
Index MDS TBR 2.33  0.44 2.03  0.48 11.8 0.037
Total cholesterol, mg/dl 364.7  117.9 189.2  54.6 45.1 <0.001
LDL cholesterol, mg/dl 284.3  118.0 127.3  49.8 51.2 <0.001
HDL cholesterol, mg/dl 52.1  16.8 55.1  20.1 þ5.4 0.224
Triglycerides, mg/dl 114.0 [97.5–237.1] 103.1 [75.2–137.5] 16.6 0.18
Lipoprotein(a), mg/l* 73.0 [43.3–400.5] 29.5 [19.3–174.5] 56.4 0.043
CRP, mg/l* 1.5 [0.6–5.5] 4.5 [1.1–9.3] þ77.7 0.12
Values are mean  SD, n (%), or median [IQR]. *Post-apheresis values of lipoprotein(a) and CRP were available
from apheresis-naive patients only (n ¼ 6).
MDS ¼ most diseased segment; TBR ¼ target-to-background ratio; other abbreviations as in Table 1.
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undergoing apheresis were intolerant of statins.
After lipoprotein apheresis, LDL-C levels were sig-
niﬁcantly reduced compared with baseline (284 
118 mg/dl vs. 127  50 mg/dl; p < 0.001), which
corresponded to a mean acute LDL-C reduction of
51  23%. Online Figure 1 displays the LDL-C levels
during the apheresis treatment period of the
apheresis-naive patients. We observed a signiﬁcant
reduction of arterial wall inﬂammation (TBR) after
LDL apheresis in the mean arterial TBR (aorta and
carotids) (2.05  0.31 vs. 1.91  0.33; p ¼ 0.02)
(Figure 2A) and in MDS TBR of index vessel (2.31 
0.44 vs. 2.03  0.48; p ¼ 0.03) (Figure 2B). Corre-
sponding reductions in mean arterial TBR and index
MDS TBR were 6.47  8.08% and 11.8  14.2%,
respectively. Notably, in the 6 non–apheresis-naive
patients, follow-up PET/CT imaging was performed
after a single cycle of lipoprotein apheresis (median
interval [IQR]: 3 days [range: 1 to 5 days]). In that
subgroup, the index MDS TBR was signiﬁcantly
reduced after a single cycle of apheresis (TBR: 2.05 
0.29 vs. 1.73  0.13 pre- vs. post-apheresis, respec-
tively; p ¼ 0.03).
Online Table 1 summarizes TBR values of individ-
ual arteries before and after lipoprotein apheresis.
Although LDL-C reduction post-apheresis was greaterin apheresis-naive subjects (222  76 mg/dl vs. 91
 69 mg/dl; p ¼ 0.01), there was no signiﬁcant dif-
ference in change of arterial TBR between apheresis-
naive subjects and patients who previously had
undergone lipoprotein apheresis (p ¼ 0.39). Mean
arterial TBR and TBR in the MDS of the index vessel
strongly correlated with baseline LDL-C (R ¼ 0.71;
p ¼ 0.01 and R ¼ 0.59; p ¼ 0.04, respectively)
(Figure 3), but not after lipoprotein apheresis (R ¼
0.42; p ¼ 0.17 and R ¼ 0.44; p ¼ 0.18, respectively).
We did not observe a signiﬁcant change in HDL-C, TG,
or CRP after lipoprotein apheresis, whereas we did
see reduced Lp(a) levels (Table 2). Additionally,
changes in arterial TBR did not correlate with changes
in CRP (p ¼ 0.21), TG (p ¼ 0.16), HDL-C (p ¼ 0.20), or
Lp(a) (p ¼ 0.78).
DISCUSSION
In the present study, we demonstrate that patients
with FH, characterized by severely elevated plasma
LDL-C levels, have markedly increased arterial wall
inﬂammation compared with healthy control subjects
without a history of CVD or hyperlipidemia as deter-
mined by 18FDG-PET/CT scan. The degree of arterial
wall inﬂammation correlated with LDL-C levels
after adjusting for statin use and atherosclerotic risk
factors. After lipoprotein apheresis in 12 FH patients
who met the apheresis-treatment criteria, a signiﬁ-
cant reduction in arterial wall inﬂammation was
observed.
Previous studies that addressed inﬂammation in
FH patients have consistently reported a systemic,
proinﬂammatory state, usually expressed as in-
creased levels of plasma inﬂammatory biomarkers
such as CRP (20). Children afﬂicted by FH were
characterized by higher levels of CRP compared with
healthy control subjects (21,22). Later in life, a low-
grade inﬂammatory state was corroborated in adult
FH patients with increased CRP levels as well as
other inﬂammatory markers (23,24). We observed a
signiﬁcant correlation between baseline CRP and
arterial FDG uptake in the study subjects. This ﬁnding
aligns with prior observations concluding that both
arterial FDG uptake and CRP are surrogate markers
of arterial inﬂammation. Moreover, arterial TBR was
reduced signiﬁcantly after lipoprotein apheresis. In
line with previous studies, we did not ﬁnd a correla-
tion between change in CRP and arterial TBR (18).
Although numerous studies with B-mode carotid
ultrasound and magnetic resonance imaging have
conﬁrmed an increased atherosclerotic burden in FH
(25), local arterial inﬂammation and the magnitude
of its sensitivity to lipoprotein apheresis remained to
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FIGURE 3 Arterial Inﬂammation Correlates With LDL-C Level
in the Course of Lipoprotein Apheresis
Arterial FDG uptake (average TBR of aorta and carotids) (A) and
TBR in MDS of the index vessel (B) signiﬁcantly correlated with
LDL-C levels at baseline before, but not after, lipoprotein
apheresis (R ¼ 0.42; p ¼ 0.17 and R ¼ 0.44; p ¼ 0.18, for mean
arterial TBR and TBR in MDS, respectively). The regression lines
and correlation coefﬁcients represent the baseline data only
(salmon dots). Individual subjects are numerically labelled.
Abbreviations as in Figures 1 and 2.
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FIGURE 2 Arterial Inﬂammation Reduction After
Lipoprotein Apheresis
Arterial 18FDG uptake is signiﬁcantly reduced after LDL apheresis
of 12 FH patients compared to baseline as assessed by average
arterial TBR (aorta and carotids) (2.05  0.31 vs. 1.91  0.33;
p ¼ 0.02) (A) and index MDS TBR (2.31  0.44 vs. 2.03  0.48;
p ¼ 0.037) (B). Corresponding reductions in mean arterial TBR
and index MDS TBR were 6.47  8.08% and 11.8  14.2%,
respectively. Error bars represent standard error of mean.
18FDG ¼ 18F-ﬂuorodeoxyglucose; LDL ¼ low-density lipoprotein;
MDS ¼ most diseased segment; other abbreviations as in
Figure 1.
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1423be investigated. The beneﬁcial effect of lipoprotein
apheresis at the vascular function level has previ-
ously been demonstrated by Igarashi et al. (26), who
reported improved endothelial function after lipo-
protein apheresis. Recently, PET/CT studies have
been introduced as an imaging modality to quantita-
tively assess inﬂammation within the vessel wall
(27). Subsequent studies showed that an increased
TBR correlated with macrophage content (13) as well
as with gene expression markers for plaque vulnera-
bility in atherosclerotic lesions (28). Further,
increased 18FDG uptake has been associated with the
presence of high-risk plaque morphology (29) and
with atherosclerosis progression (30). Moreover, the
arterial FDG-PET signal is linked to an increased riskof CV events (31,32) and recurrent cerebral infarction
(4), and has been shown to be a potent predictor of
future CVD after multivariate adjustment (14). Here,
we demonstrated that increased local arterial wall
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1424inﬂammation in patients with FH, irrespective of
statin use and other potential confounding factors,
was modiﬁable by lipoprotein-apheresis treatment
(Central Illustration). This observation underlines the
close correlation between elevated lipoprotein levels
and inﬂammatory activation within the arterial wall.
Most studies addressing anti-inﬂammatory ef-
fects of medications in CVD patients have used
statins as an LDL-C–lowering agent, because statins
exert numerous pleiotropic effects, including anti-
inﬂammatory properties (15,33). To address the im-
pact of atherogenic lipoprotein-lowering therapy
independent from pleiotropic effects, we applied
lipoprotein apheresis in eligible FH patients. Here, we
observed that the magnitude of reduction in arterial
TBR seen with apheresis appears to be similar to that
seen with high-dose statins (15). However, it also is
apparent that statins are associated with a somewhat
greater reduction in arterial inﬂammation per mg/dl
reduction in LDL-C. For example, in a prior study
evaluating the effects of atorvastatin on arterial
inﬂammation, each 10% reduction in LDL-C was
associated with a 2.9% and 3.2% reduction in MDS TBR
in the 10-mg and 80-mg atorvastatin groups, respec-
tively (15). With apheresis, the absolute change in
arterial TBR was relatively smaller in magnitude
compared with changes in LDL-C; each 10% reduction
in LDL-C induced a 2.1% reduction in MDS TBR. Thus,CENTRAL ILLUSTRATION Impact of Apheresis on Circulating Lipi
Familial hypercholesterolemia (FH) is associated with elevated circulatin
apheresis in individuals with FH results in a rapid reduction in circulatin
inﬂammation, measured as a decrease in arterial ﬂuorodeoxyglucose upon one hand, the signiﬁcant reduction in arterial PET
signal observed after apheresis demonstrates that
nonpharmacological LDL-C lowering per se results in
reduced atherosclerotic inﬂammation independently
of the pleiotropic effects of pharmacotherapy. On
the other hand, the fact that statins are associated
with a modestly higher reduction in arterial inﬂam-
mation per unit reduction in LDL-C supports the
concept that a portion—albeit a limited one—of statins’
anti-inﬂammatory actions may also relate to pleio-
tropic effects.
We also observed a numerically higher reduction in
TBR of carotids compared with the aorta by apheresis;
a prior study evaluating the effect of high-dose ator-
vastatin on arterial inﬂammation made a similar
observation (15). The potential superiority of carotids
to aorta as an imaging endpoint has been previously
suggested (18). Although it is not fully understood
why, after lipid lowering, reductions in arterial
inﬂammation (by PET/CT) may be more evident in the
carotids over the aorta, which may be potentially due
to biological differences in vessel walls or technical
issues relating to the PET/CT imaging approach (18).
It is worth noting that reductions in arterial FDG
uptake occurred very rapidly in this study. In the
subset of non–apheresis-naive subjects who under-
went a single session of apheresis, the arterial PET
signal was substantially reduced within a median ofds and Atherosclerotic Inﬂammation
g lipids and increased atherosclerotic inﬂammation. Lipoprotein
g lipids as well as in a concordant reduction in atherosclerotic
take.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The arterial
walls of patients with FH are characterized by inﬂammatory
activity, which can be assessed by 18F-ﬂuorodeoxyglucose
imaging positron emission tomography, and removal of
low-density lipoprotein cholesterol by lipoprotein-apheresis
reduces inﬂammation.
TRANSLATIONAL OUTLOOK: The effect of non-
statin lipoprotein-lowering strategies that attenuate
vessel wall inﬂammation on clinical ischemic events
in patients with atherosclerosis warrants further
investigation.
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14253 days after apheresis. Prior studies in humans have
noted that lipid lowering with statins produces re-
ductions in arterial FDG uptake within 4 weeks (the
earliest time point previously assessed). The current
study shows that functional changes in the human
artery wall occur even earlier, comparable to that
demonstrated in animal studies (34).
Finally, it is notable that the magnitude of reduc-
tion in arterial TBR in our study is comparable to the
impact potent anti-inﬂammatory agents, such as anti-
tumor necrosis factor (TNF)-a therapy, exert on vessel
wall inﬂammation. Recently, it was reported that af-
ter 8 weeks of treatment with a TNF-a antagonist in
patients with rheumatoid arthritis, the TBR across
the aorta was reduced by 6% (35). Collectively, these
data support a direct, strong role of atherogenic
lipoprotein particles including LDL-C in driving
atherogenic vascular inﬂammation, which implies
that all potent atherogenic lipoprotein-lowering
therapies might contain the potential to attenuate
vessel wall inﬂammation in hyperlipidemic, athero-
sclerotic patients.
STUDY LIMITATIONS. When interpreting the results
of this study, several limitations need to be consid-
ered. First, matching between FH patients and con-
trols was not optimal. For example, BMI was higher
in FH patients compared with controls. Because
higher BMI has been associated with increased 18FDG
uptake, this may have contributed to the higher
signal in FH in our study (36). However, this effect is
partly counterbalanced by the more advanced age
of controls, which can be expected to result in an
increased 18FDG uptake (36). Overall, the matching
is unlikely to have been of major inﬂuence, because
the relation between LDL-C and TBR was retained
after adjustment for confounding factors, including
both BMI and age.
Second, lipoprotein apheresis affects other plasma
factors beyond apoprotein B–containing lipoproteins
(37), including inﬂammatory proteins and oxidized
phospholipids (38). Part of these factors are bound
to LDL-C and/or Lp(a), making it impossible to sepa-
rate the impact of pure atherogenic lipoprotein
lowering from the impact of lowering of their asso-
ciated proinﬂammatory molecules. TBR change was
signiﬁcantly correlated with LDL-C change, whereas
no correlation could be demonstrated for Lp(a), sug-
gesting that most of the TBR change appears to be
LDL-C driven. However, we cannot exclude the pos-
sibility that changes in other plasma factors may have
contributed to the TBR decrease.
Additionally, this study had a small sample size,
especially in the treatment group, and we did not
incorporate a control treatment arm in this study.CONCLUSIONS
The present data indicate that prolonged and severe
elevation of atherogenic apoprotein B–containing
lipoproteins comprising LDL-C are important drivers
of arterial wall inﬂammation. The latter remains,
however, amenable to improvement as attested by a
signiﬁcant decrease of vessel wall FDG uptake
after short-term lipoprotein apheresis. The fact that
TBR in FH patients was higher at baseline, indepen-
dent from statin use, combined with a TBR decrease
after lipoprotein apheresis, lends further support
to therapeutic efforts aimed at aggressive lowering
of atherogenic lipoprotein particles, particularly in
patients with severe LDL-C elevations and an
increased CVD risk. Our ﬁndings emphasize the
relevance of incorporating vessel wall inﬂamma-
tion imaging into future studies aimed at lowering
atherogenic lipoprotein particles, particularly in
high-risk patients with persistent LDL-C elevation.
Moreover, the ﬁndings support the contention that
nonpharmacological lipoprotein removal directly
reduces arterial inﬂammation.
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